Search PubMed⌕ Search

Biomedical subjects

J E Mitchell

Publications and source records attributed to J E Mitchell.

At least 109 records · Page 6Linked to original sources
PubMed1989

A placebo-controlled, double-blind crossover study of naltrexone hydrochloride in outpatients with normal weight bulimia.

The endogenous opioid system plays an important role in the control of feeding behavior. Previous research has shown that antagonism of endogenous opioids will suppress feeding in certain models in both human and infrahuman species. In the current study, 16 normal-weight bulimic women were treated with low-dose naltrexone, the long-acting, orally active narcotic antagonist, and placebo in a crossover design. The use of the active drug was not associated with a clinically significant reduction in binge eating or vomiting episodes. Suggestions for further research in this area are offered.

Adult↗
PubMed1989

Masculinity and femininity in twin children: genetic and environmental factors.

Genetic and environmental origins of individual differences in masculine and feminine personality attributes were investigated in a sample of 38 monozygotic and 32 dizygotic twin pairs (total N = 140) during pre- and early adolescence. Self-report measures of both masculine and feminine characteristics were obtained for each child using 2 standardized instruments: the Children's Personality Attributes Questionnaire (CPAQ) and the Adolescent Self-Perception Inventory (ASPI). Multivariate biometrical analyses revealed significant genetic influences in all measures, accounting for 20%-48% of the observed variation in each. Environmental influences, which explained the remaining 52%-80% of variance in masculinity and femininity, were apparently specific to each individual and not shared by members of the same twin pair. The results underscore the importance of considering both genetic and environmental factors in gender-role development, particularly in studies of family resemblance.

Adolescent↗
PubMed1989

Response to alternative antidepressants in imipramine nonresponders with bulimia nervosa.

The authors report the results of open-label antidepressant trials in a series of normal weight bulimic women who showed an inadequate response to an initial trial of imipramine hydrochloride as part of a treatment comparison study. The results indicate that a significant percentage of subjects responded to a second trial of an alternative agent. Overall, 47% had a complete remission of symptoms during the second trial, usually with a monoamine oxidase inhibitor or fluoxetine. The authors stress the importance of persisting in trials of alternative agents if bulimic patients fail to respond to an initial trial.

Adolescent↗
PubMed1988

Bulimia with and without a family history of drug abuse.

Patients evaluated in an eating disorders clinic and found to meet DSM-III criteria for bulimia were classified as to the presence or absence of a family history of drug abuse in at least one first-degree relative. Patients with a positive family history of drug abuse (N = 102, 37.1%) did not differ significantly from patients without this history (N = 173, 62.9%) on the variables of age at evaluation and age of onset of eating disorder, or as to their pattern or severity of bulimic behaviors, including binge-eating, self-induced vomiting, and laxative abuse. However, the patients with a family history of drug abuse were more likely to have experienced drug abuse problems themselves, to have been treated for chemical dependency prior to being evaluated for their eating disorder and to have a history of having been overweight. Those in the positive family history group also reported more family disruption.

Adult↗
PubMed1988

Diuretic use as a marker for eating problems and affective disorders among women.

Fourteen female symptomatic volunteers between the ages of 18 and 40 who used diuretics on a regular basis for reasons that were not medically necessary were evaluated. Seven (50%) were diagnosed as having a current or past syndromal or subsyndromal eating disorder, and 9 (64%) were diagnosed as having a current or past affective disorder. The results of this pilot study suggest that chronic diuretic use in young women should signal to the clinician the possibility of an unrecognized eating problem and/or an affective disorder.

Adolescent↗
PubMed1988

Prescription diuretic abuse in patients with bulimia nervosa.

Bulimia nervosa, a common eating disorder usually characterized by binge eating and self-induced vomiting, may also involve abuse of prescription diuretics. This article describes four patients who abused prescription diuretics in large quantities (up to 2 g/d of furosemide) for extended periods of time. Physical examination and laboratory values provided few clues to the diagnosis of bulimia nervosa. Other eating-related behaviors previously linked to bulimia nervosa--including abuse of diet pills, illicit amphetamines, and laxatives, as well as withholding of insulin in one diabetic patient--were present in these cases. Usually the patients' primary physicians were not aware of these problems. Physicians should be aware that patients requesting prescription diuretics may have bulimia nervosa.

Adult↗
PubMed1988

Diarrheal infections.

Infectious agents usually cause diarrhea by invading and damaging the intestinal mucosa or by producing enterotoxins that alter the secretory and absorptive capacities of the intestinal mucosa. Some infectious agents may do both. Physical malabsorption produced by proliferative outgrowth of bacteria or protozoa may also occur. Rotavirus is the most common cause of pediatric infectious diarrhea in the United States. Escherichia coli and Campylobacter species are the most common bacterial agents.

Anti-Bacterial Agents↗
PubMed1987

High-dose naltrexone therapy and dietary counseling for obesity.

There is considerable evidence that antagonism of the endogenous opioids will suppress food intake in a variety of animal species. The authors report a double-blind, placebo-controlled trial of the long-acting, orally active narcotic antagonist naltrexone in the promotion of weight loss in obese male subjects who were also undergoing dietary counseling for weight reduction. Subjects received medication (naltrexone, 300 mg/day or placebo) for 8 weeks following an initial 2-week single-blind placebo phase. The results failed to demonstrate an advantage for the active drug. However, the naltrexone was associated with hepatotoxicity when used at this dosage in this population.

Adult↗
PubMed1987

Eating disorders.

Explore the source record for details and available documents.

Feeding and Eating Disorders↗